Pfizer faces setback as Reckitt Benckiser and GSK withdraw from $20bn consumer health deal
Pfizer’s $20 Billion Sale Stalls: In a significant turn of events in the pharmaceutical industry, both Reckitt Benckiser and GlaxoSmithKline (GSK) have decided to withdraw from acquisition talks with Pfizer regarding its consumer healthcare business. This decision marks a setback for Pfizer’s plans to offload this segment, valued at approximately $20 billion. Overview of Pfizer’s […]